Global pharmaceutical company Novo Nordisk is launching its latest innovation in diabetes medication in Egypt, with its once-weekly Ozempic® for the treatment of type 2 diabetes now available in the country.

"With its superior and unique clinical profile, we believe that Ozempic® has the potential to set a completely new standard for the treatment of type 2 diabetes. Due to its outstanding clinical benefits as well as reduction of cardiovascular diseases risk by 26%,” said Professor Samir George, Professor of Internal Medicine and Diabetes at Cairo University.

The medicine, in conjunction with diet and exercise, helps manage blood sugar and body weight, and reduces the risk of heart problems for people living with type 2 diabetes. It can be used either alone or in addition to other products for diabetes management.

As mentioned by Dr. Hesham El Hefnawy Professor of diabetes and endocrinology and Ex-Dean of the National institute of Diabetes, Head of national non-communicable diseases committee “Type 2 diabetes is a complex disease. It develops when a person’s body cannot effectively use, or cannot make enough insulin, which helps regulate how much sugar is in the blood. Without insulin, too much sugar stays in the bloodstream where it can cause damage to vital organs and result in serious health problems.”

“I see many people in my clinic each week with uncontrolled diabetes; in fact, nearly half the people living with type 2 diabetes do not have their condition in control, and are at risk of serious complications, such as cardiovascular disease, kidney diseases, retinopathy and neuropathy” said Professor Yehia Ghanem Professor of Diabetes and Metabolism at Alexandria University.

“Ozempic® is available in Egypt following of a series of clinical trials involving over 10,000 adults with type 2 diabetes. The results consistently showed greater reductions in both blood sugar and body weight compared with commonly used treatments for type 2 diabetes, as well as cardiovascular benefits, in people with  2 diabetes.” elaborated professor Abbas Oraby, Professor of Diabetes and Endocrinology, Zagazig University.